These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8898065)

  • 1. Severe insulin resistance treated with insulin lispro.
    Henrichs HR; Unger H; Trautmann ME; Pfützner A
    Lancet; 1996 Nov; 348(9036):1248. PubMed ID: 8898065
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe insulin resistance treated with insulin lispro.
    Gill G; Williams G
    Lancet; 1997 Jan; 349(9046):211. PubMed ID: 9111571
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement in severe insulin resistance with frequent injections of lispro insulin.
    Raine CH; Krzyston MJ; Amr M; Hydrick L
    J Natl Med Assoc; 1999 Jul; 91(7):410-3. PubMed ID: 10643214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis.
    Umpierrez GE; Latif K; Stoever J; Cuervo R; Park L; Freire AX; E Kitabchi A
    Am J Med; 2004 Sep; 117(5):291-6. PubMed ID: 15336577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early postprandial hypoglycemia following administration of lispro insulin.
    Strachan MW; Frier BM
    Diabetes Care; 1997 Jul; 20(7):1214-5. PubMed ID: 9203474
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus.
    Jehle PM; Fussgänger RD; Seibold A; Lüttke B; Böhm BO
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):498-503. PubMed ID: 8937933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of lispro insulin: control of postprandial glucose levels is within reach.
    Bohannon NJ
    Postgrad Med; 1997 Feb; 101(2):73-6, 79-80. PubMed ID: 9046927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of hypoglycemic brittle diabetes with peripheral edema successfully managed by conversion from insulin lispro to insulin aspart.
    Tone A; Shikata K; Nakagawa K; Hashimoto M; Makino H
    Diabetes Res Clin Pract; 2008 Sep; 81(3):e15-6. PubMed ID: 18676048
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin lispro--a review.
    Muzaffer Z; Iqbal A; Ristic S
    J Pak Med Assoc; 1998 Jul; 48(7):212-4. PubMed ID: 10067027
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin lispro: a fast-acting insulin analog.
    Noble SL; Johnston E; Walton B
    Am Fam Physician; 1998 Jan; 57(2):279-86, 289-92. PubMed ID: 9456992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G; Del Prato S; Arcari R; Bellomo Damato A; Benzi L; Bruttomesso D; Calderini MC; Coscelli C; Fedele D; Galluzzo A; Giordano M; Giorgino R; Lapolla A; Orsini P; Pagano G; Santoro D; Riccardi G
    Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin lispro: new preparation. Faster acting.
    Prescrire Int; 1998 Jun; 7(35):67-8. PubMed ID: 10342918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes.
    Darmon P; Curtillet C; Boullu S; Laugier A; Dutour A; Oliver C
    Diabetes Care; 1998 Sep; 21(9):1575. PubMed ID: 9727917
    [No Abstract]   [Full Text] [Related]  

  • 15. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
    Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
    [No Abstract]   [Full Text] [Related]  

  • 16. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
    Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
    Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus.
    Herz M; Arora V; Campaigne BN; Scholtz HE; Potgieter MA; Mollentze W
    S Afr Med J; 2003 Mar; 93(3):219-23. PubMed ID: 12768948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.